Takizawa, Tsubasa
Ohtani, Seiya
Watanabe, Narumi
Miyazaki, Naoki
Ishizuchi, Kei
Sekiguchi, Koji
Iba, Chisato
Shibata, Mamoru
Takemura, Ryo
Hori, Satoko
Nakahara, Jin
Article History
Received: 2 August 2022
Accepted: 21 December 2022
First Online: 31 December 2022
Declarations
:
: This study was approved by Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute’s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: TT serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. TT received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, and Santen Pharmaceutical and research funding from Eli Lilly Japan and Tsumura outside the submitted work. MS serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. MS received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, and Amgen and research funding from Otsuka outside the submitted work. JN received honoraria and research scholarships from Daiichi Sankyo. The remaining authors have no relevant financial or non-financial interests to disclose.